Drug discovery remains a very long and costly process with reducing attrition a major objective. We have shown previously that using human genetics evidence may increase the chance of success in the clinic for drug targets. In addition, genomics technologies that can measure omics layers or perturb the genome at scale can also be used to identify and validate new drug targets and investigate biology at a systems level. In this talk, using examples, I will describe how genetics and genomics data with computational biology analyses are currently being used in drug discovery and the importance of biological context.